Divis Laboratories Ltd share Price Today

Divi’s is engaged in manufacturing generic APIs and intermediates, custom synthesis (CS) of active ingredients and advanced intermediates for pharma MNCs, other speciality chemicals like Carotenoids and complex compounds like peptides and Nucleotide revenues.

• In CS, the company maintains strong relationship with global big pharma players while in generics it enjoys significant market share in products like Naproxen, Dextromethorphan and Gabapentin among others
• Divi’s is fully backward integrated in products with high market share. The management intends to follow suit in other products

 

• Sales were up 46.5% YoY to ₹ 2493.2 crore
• EBITDA was at ₹ 1097.2 crore, up 58.7% YoY with margins at 44%
• Consequent PAT was at ₹ 902.2 crore (up 91.7% YoY)

Pharmaceuticals company Divi's Laboratories announced Q3FY24 & 9MFY24 results:

Consolidated Q3FY24:

• Total Income: Rs 1,950 crore, compared to Rs 1,821 crore in the corresponding quarter of the previous year.
• Material Consumption: Approximately 39% of sales revenue.
• Profit Before Tax (PBT): Rs 489 crore, compared to Rs 435 crore in the corresponding quarter of the previous year.
• Profit After Tax (PAT): Rs 358 crore, compared to Rs 306 crore in the corresponding quarter of the previous year.

Standalone Q3FY24:

• Total Income: Recorded at Rs 1,902 crore in Q3FY24 compared to Rs 1,807 crore in Q3FY23.
• Profit Before Tax (PBT): Stood at Rs 490 crore in Q3FY24, up from Rs 439 crore in Q3FY23.
• Profit After Tax (PAT): Amounted to Rs 358 crore in Q3FY24, higher than the Rs 310 crore in Q3FY23.
• Forex Gain: Registered at Rs 17 crore in Q3FY24, decreased from Rs 49 crore in Q3FY23.

Consolidated 9MFY24:

• Total Income: Rs 5,804 crore, compared to Rs 6,099 crore in the corresponding previous period.
• Profit After Tax (PAT): Rs 1,062 crore, compared to Rs 1,502 crore in the corresponding previous period.
• Forex Gain: Rs 32 crore, compared to Rs 134 crore in the previous 9-month period.

Standalone 9MFY24:

• Total Income: For 9MFY24, it amounted to Rs 5,665 crore, down from Rs 6,003 crore in 9MFY23.
• Profit Before Tax (PBT): For 9MFY24, it was Rs 1,432 crore, a decrease from Rs 1,886 crore in 9MFY23.
• Profit After Tax (PAT): For 9MFY24, it reached Rs 1,045 crore, down from Rs 1,489 crore in 9MFY23.
• Forex Gain: For 9MFY24, it stood at Rs 29 crore, a decline from Rs 137 crore in 9MFY23.

Result PDF